Keywords
Non Small Cell Lung Cancer ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

416 Search results.

Eligibility Non Small Cell Lung Cancer (NSCLC) NCT01210378

- 1/22/21 - 1 form, 1 itemgroup, 17 items, 1 language
Itemgroup: Inclusion Criteria
Nitroglycerin in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01210378

Eligibility Solid Tumors, NSCLC, Biliary and Bladder Cancer NCT02240238

- 10/1/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02240238

Eligibility Lung Cancer, Non-Small Cell NCT01772225

- 7/10/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
NSCLC Burden of Illness Study; ODM derived from: https://clinicaltrials.gov/show/NCT01772225

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01933932

- 7/4/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT01933932

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01750281

- 7/4/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.; ODM derived from: https://clinicaltrials.gov/show/NCT01750281

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV; NCT01809210

- 7/4/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01809210

Eligibility Locally Advanced or Metastatic Non-small Cell Lung Cancer. NCT01526928

- 7/4/20 - 1 form, 1 itemgroup, 29 items, 1 language
Itemgroup: Criteria
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01526928

Eligibility Locally Advanced Non Small Cell Lung Cancer (NSCLC)* NCT01118676

- 7/4/20 - 1 form, 2 itemgroups, 27 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01118676

Eligibility Non-Small Cell Lung Cancer NCT02468661

- 4/25/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification; ODM derived from: https://clinicaltrials.gov/show/NCT02468661

Eligibility INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER NCT01757288

- 4/20/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT01757288

Eligibility Inoperable Locally Advanced Non Small Cell Lung Cancer NCT01933568

- 4/20/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.; ODM derived from: https://clinicaltrials.gov/show/NCT01933568

Eligibility NSCLC NCT01290809

- 3/30/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01290809